@invitewellnessllc's testosterone claims need context

What did @invitewellnessllc actually say?

The creator made a straightforward argument: there is no universal testosterone dose, "everyone gets 200 milligrams once a week" is wrong, and the right dose is whatever resolves your symptoms while keeping labs stable. They said injection frequency should also be individualized, not copied from someone else's protocol.

To be fair, this is a reasonable premise. The creator is not pushing a specific product, not prescribing anything, and not making wild efficacy claims. They are arguing for patient-centered titration, which is a defensible clinical position. The pointed skepticism toward flat 200mg weekly dosing is the most specific claim they made, and it deserves closer examination.

Does the science back this up?

Mostly, yes. The individualization argument is well-supported, though the implicit dismissal of 200mg weekly as a starting dose is more complicated than the creator lets on.

Clinical guidelines from the American Urological Association (AUA, 2018) and the Endocrine Society (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism) both emphasize titrating testosterone to symptom response and laboratory targets rather than fixed universal doses. The Endocrine Society recommends targeting a mid-normal range serum testosterone, typically 400 to 700 ng/dL, and adjusting dose accordingly. That is individualization by definition.

On injection frequency, testosterone cypionate and enanthate have half-lives of roughly 7 to 8 days, which means once-weekly injections create significant peak-and-trough swings in serum levels. Ramasamy et al. (2014, Journal of Urology) noted that more frequent, smaller injections tend to produce more stable levels. This supports the creator's point about frequency being a real variable worth optimizing.

What did they get wrong (or right)?

The creator mostly got the conceptual framework right. Where they oversimplify is in dismissing 200mg weekly as if it is obviously reckless. It is not obviously reckless. It is a commonly prescribed starting point, and for some patients, it produces appropriate mid-normal testosterone levels. The problem is not the number itself. The problem is using it without follow-up labs and dose adjustment.

The creator's framing, "if you're doing 200 milligrams once a week injection, look into that," implies the dose is wrong by default. That is an overreach. Testosterone cypionate 200mg weekly produces serum levels that vary substantially between individuals based on SHBG, body composition, and metabolism. For a large man with high SHBG, 200mg weekly might be appropriate. For a smaller man with low SHBG, it might produce supraphysiologic levels. Context is everything, and the creator skips over that nuance.

What they got right: the emphasis on symptom resolution plus stable labs as the dual signal for a correct dose is genuinely sound clinical thinking. Neither labs alone nor symptoms alone are sufficient endpoints.

What should you actually know?

Individualized TRT dosing is not a fringe idea. It is what guidelines actually recommend, and it contrasts with the "one-size" protocols that some clinics do, unfortunately, use. But individualization requires ongoing lab monitoring, not just symptom self-reporting.

The key labs to track include total testosterone, free testosterone, estradiol, hematocrit, and PSA. Bhasin et al. (2018) recommend checking testosterone levels 3 to 6 months after starting or adjusting therapy. Hematocrit is especially important because testosterone stimulates erythropoiesis, and elevated hematocrit increases clotting risk.

Injection frequency matters more than many patients realize. Twice-weekly or even every-3.5-day injections of the same total weekly dose can reduce peak-trough variability significantly, which often improves mood stability and reduces estradiol spikes. This is a practical optimization that is underused in standard care.

• Total testosterone target for most men on TRT: 400 to 700 ng/dL mid-cycle (Endocrine Society, 2018)
• Hematocrit should not exceed 54 percent during treatment (AUA guidelines, 2018)
• Symptom resolution alone is not enough — labs confirm whether levels are actually in a safe range
• More frequent smaller injections reduce variability for most patients using testosterone cypionate or enanthate